Pharma Industry News

Data show J&J’s Invokana may slow or prevent CKD in diabetes patients

The data provides the first significant update in nearly 20 years regarding slowing the progression of CKD in patients with type II diabetes.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]